Low non-cytotoxic doses of ETAP-Lab’s human amyloid beta 1-42 oligomers (AβO) are disrupting functional neuronal network activity in NETRI’s microfluidic device coupled with MEA. This result is an important milestone towards a more relevant and physiological model of Alzheimer’s disease for drug screening and mechanistic studies.
For more information download the Application Note
#alzheimer #DrugScreening #microfluidics #neuroscience
